Pharmaceuticals' association vfa confirms innovation trend
Germany's Association of Research-Based Pharmaceutical Companies, the vfa, has said that innovation remains a trend in the country's pharmaceutical industry. The vfa's statement came after the release of the country's latest annual Arzneiverordnungs-Report on medicines prescribed for statutory health insurance fund patients.
The vfa noted that Germany's pharmaceutical industry is highly innovative, citing breakthroughs that include a treatment that can cure more than 90 percent of the cases of hepatitis C. The association pointed out that advances continue to be made in drugs for treating certain types of cancer, as well. It added that new medicines mean cancer patients are living longer and with better quality of life.
The vfa's statistics confirm this trend. Since 1990, year-for-year Germany's research-based pharmaceutical companies have brought an average of 25 new medicines to market. Yet in the last several years, this figure has been at least 25 percent higher.
The vfa observed that even as innovation continues, patents are also due to expire on some "blockbuster" drugs for treating certain types of cancers and arthritis. The association concluded that this would mean reduced healthcare spending on these innovative products.
The publishers of the Arzneiverordnungs-Report say that the analysis in the report is evidence-based and founded on information professionally shared by doctors, pharmacists and statutory health insurance funds. Among Arzneiverordnungs-Report's aims are ensuring the country's pharmaceuticals' market remains transparent and assessing drug efficacy.
The vfa represents the interests of 42 leading manufacturers of pharmaceuticals and more than 100 of their subsidiaries with respect to healthcare, research and economic policy. It is a member of HEALTH MADE IN GERMANY's Pharmaceutical Industry Working Group.